Beschreibung:
Acute coronary syndromes (ACS) is an umbrella term used to describe a series of signs and symptoms indicative of myocardial ischemia, comprising unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction.
"1 Preface.- 2 Epidemiology - US, European, and global perspectives; unstable angina, NSTEMI, STEMI.- 3 Diagnosis - symptoms, biomarkers, ECG.- 4 Risk stratification - TIMI risk score, GRACE risk score, CRUSADE/PURSUIT risk score.- 5 Medical therapy - antithrombotics, statins, etc.- 6 Percutaneous therapy - culprit vessel versus mulitvessel; BMS vs DES.- 7 Surgical therapy.- 8 Prognosis. - 9 Controversies - optimal antithrombotic strategy, fibrinolysis versus primary PCI for STEMI, preferred mode of revascularization (bare metal stents versus drug eluting stents versus CABG). - 10 Future approaches - CT angio and other evolving imaging modalities, biomarkers, proteomics, genomics, angiogenesis, myogenesis. Appendix A - Practice Guidelines - ACC/AHA and ESC.- Appendix B - Synopsis of Key Trials."
1 Preface.- 2 Epidemiology - US, European, and global perspectives; unstable angina, NSTEMI, STEMI.- 3 Diagnosis - symptoms, biomarkers, ECG.- 4 Risk stratification - TIMI risk score, GRACE risk score, CRUSADE/PURSUIT risk score.- 5 Medical therapy - antithrombotics, statins, etc.- 6 Percutaneous therapy - culprit vessel versus mulitvessel; BMS vs DES.- 7 Surgical therapy.- 8 Prognosis. - 9 Controversies - optimal antithrombotic strategy, fibrinolysis versus primary PCI for STEMI, preferred mode of revascularization (bare metal stents versus drug eluting stents versus CABG). - 10 Future approaches - CT angio and other evolving imaging modalities, biomarkers, proteomics, genomics, angiogenesis, myogenesis. Appendix A - Practice Guidelines - ACC/AHA and ESC.- Appendix B - Synopsis of Key Trials.